Testing GD2 CAR T Cells in Children and Young Adults With Brain Tumors
Original title: GD2-CAR T Cells for Pediatric Brain Tumours
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test of the treatment in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests changed immune cells in young people whose brain tumor came back.
Who this trial is for. This trial is for children and young adults with a brain or spinal cord cancer that came back or did not respond to treatment. It tests immune cells, called CAR T cells, changed to target a marker named GD2. The cells also carry a built in safety switch.
Where it stands. The trial is measuring how safe this treatment is and how well it works. Those answers are not in yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: Someone who fits this picture could ask their care team about this study. The care team can explain what taking part would involve. Only the trial team decides who can join.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test, not care your own doctor can give you. Being in a trial is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, September 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.